Search

The present article provides a personalized account of our recent work on the synthesis of substituted and fused five-membered heterocycles using various organosulfur building blocks, derived primarily through base-mediated condensation of active methylene compounds with (het)aryl/alkyl dithioesters, which have not been previously explored. We initially describe the ring-opening transformations of 4-[(methylthio)-(het)aryl-methylene]-2-phenyl-5-oxazolones, leading to the synthesis of functionalized oxazoles, thiazoles, and bisoxazoles. We then go on to focus on the synthesis of substituted benzothiophenes, indoles, and benzofurans, as well as their hetero-fused analogs. These compounds are synthesized via transition-metal-catalyzed intramolecular C–heteroatom (C–S, C–N, C–O) bond formation (via cross-coupling or C–H bond functionalization) of various reactive organosulfur intermediates, derived from base-mediated condensation of 2-bromo(het)arylacetonitriles, acetates, or desoxybenzoins or the corresponding 2-unsubstituted precursors. Finally, we highlight the synthetic applications of a new class of previously unexplored organosulfur building blocks, namely, unsymmetrically substituted 1,3-bis(het)aryl-1,3-monothioketones, derived via base-mediated condensation of ketones with (het)aryl/alkyl dithioesters, for the regioselective synthesis of substituted pyrazoles, isoxazoles, thiophenes, imidazoles, and benzothiophenes. 1 Introduction 2 4-[(Methylthio)-het(aryl)-methylene]-2-phenyl/2-(2-thienyl)-5-oxazolones: Versatile Templates for the Synthesis of Oxazoles, Thiazoles, and Bisoxazoles 3 Synthesis of Benzothiophenes, Indoles, and Benzofurans via Transition-Metal-Catalyzed Intramolecular C–Heteroatom Bond Formation 4 1,3-Bis(het)arylmonothio-1,3-diketones and 1,3-Bis(Het)aryl-3-(methylthio)-2-propenones: Versatile Intermediates for the Regioselective Synthesis of Five-Membered Heterocycles 5 Conclusion [ABSTRACT FROM AUTHOR]

An efficient, facile, and one‐pot route has been utilized for the synthesis of a new series of 3,7‐dimethyl‐1‐(5‐(2‐(4‐substitutedphenylthiazol‐2‐yl)hydrazono)hexyl)‐1H‐purine‐2,6(3H,7H)‐dione (4a–4j). The pentoxifylline (1) as a novel precursor, thiosemicarbazide, and a variety of phenacyl bromides have been employed to generate a newer pentoxifylline‐thiazole adduct using PPA as the green catalyst at reflux conditions to afford a high yield and pure product. All the synthesized compounds were purified using chromatographic methods and characterized by spectroscopic techniques (1H and 13C NMR, MS, and IR). Antioxidant activity was assessed using a DPPH free radical scavenging assay, and it was observed that compounds with cyano functional groups and electron‐donating groups showed notably higher potency, with IC50 values around 400 µM, while those with halogens and nitro functional groups displayed moderate efficacy (IC50 ≈600 µM). These results were compared to the standard ascorbic acid, which had an IC50 of 382.54 ± 5.09 µM. Molecular docking was performed on the myeloperoxidase (MPO) enzyme to explore the mechanistic basis of antioxidant activity, providing valuable insights into the thermodynamic interactions that contribute to binding affinity. [ABSTRACT FROM AUTHOR]

Background: Despite the effectiveness of the TRIO regimen in maintaining viral suppression, as seen in the ANRS 139 TRIO trial, one drawback is the high pill burden. However, with the development of newer antiretrovirals, this regimen can be simplified. The combination of both co-formulated darunavir/cobicistat and dolutegravir/rilpivirine keeps the integrity of the TRIO regimen while decreasing daily pill count from 12 to 2 tablets daily. The purpose of this case series is to demonstrate the efficacy of this regimen as there is a current lack of data. Methods: This case series included patients with no resistance to dolutegravir, rilpivirine, or darunavir, who were switched to the modified TRIO regimen between June 1st 2018 to June 1st 2022. The primary outcome was the proportion of patients with plasma HIV-RNA levels <50 copies/mL by 24 weeks. Results: At week 24, all patients (n = 9) had a HIV-RNA <50 copies/mL. At week 48, one patient did not have a VL available. However, out of the remaining 8 patients, all maintained an HIV-RNA of <50 copies/mL at week 48. Conclusion: HIV-RNA levels remained suppressed when patients were switched to the modified TRIO regimen. In addition, the pill burden was reduced which can add to overall patient satisfaction. [ABSTRACT FROM AUTHOR]

It was known that the majority of viral infections start off as cutaneous eruptions, which heal on their own in most cases. The prognosis is dependent on the state of immunologic surveillance, just like in other infectious disorders. Therefore, those who are immunosuppressed are more in danger. But recently it’s becoming increasingly clear that eruptions that were once thought to be benign diseases can really cause problems and even death, even in immunocompetent patients. Hence, in this article, our goal was to identify possible potential antiviral candidates. We have synthesized a series of bis-thiazole derivatives via the reaction of bis-thiosemicarbazone derivative 3 with hydrazonoyl chlorides and haloketones in an effort to examine their potential antiviral properties and interactions with the main protease of Coxsackievirus B. Spectroscopic methods and elemental analysis were used to corroborate the structures of the novel bis-thiazole derivatives. The most potent derivative, bis-thiazole derivative 7a, was found to have the strongest antiviral activity against Coxsackievirus B (Cox B). Further investigation into its mode of action indicated that compound 7a has a dual activity that inhibits viral adsorption and replication. The efficacy of many compounds against Coxsackievirus adenovirus targets was assessed using molecular docking. The findings revealed that compounds 7a, 7c, 11b and 11c have high binding energies, efficiently engaging the active sites of essential Cox B virus proteins such as the Coxsackievirus adenovirus receptor (CAR), 3C-protease, and RNA-dependent RNA polymerase (RdRp). These interactions involved a variety of chemical bonding types, indicating that these substances can inhibit enzyme activity while also exhibiting substantial antiviral effects involving viral replication and adsorption. Furthermore, the computational ADMET study of these compounds indicated conformance to Lipinski’s criteria, implying positive physicochemical properties. Furthermore, MD simulations demonstrated stable complexes of 7a and 11b with Coxsackievirus adenovirus receptor (CAR), 3C-protease, and RNA dependent RNA polymerase (RdRp) with RMSD (0.1–0.30, 0.20–0.30, and 0.20–0.35 nm), RMSF (0.1–0.5 nm), and SASA (80–105, 140–150, and 220–235). These outcomes further reinforce the potential of these compounds in current antiviral drug development endeavors. The collective findings underscore the potential of these compounds as candidates for antiviral therapies against Coxsackievirus adenovirus. [ABSTRACT FROM AUTHOR]

Background: Although second-generation antipsychotics (SGAs) have proven to be effective therapeutic options for patients with schizophrenia, there is a notable lack of evidence on patients' subjective perspectives regarding their well-being, quality of life, and satisfaction with these medications. This study aimed to evaluate the treatment satisfaction and effectiveness of lurasidone on quality of life and functioning in adult patients with schizophrenia in real-world Italian clinical practice. Methods: This was a multicentre, national, non-interventional, single-arm, 3-month prospective study. Patients who were naive to lurasidone treatment and whose treating physician had decided to start them on this medication were enrolled and evaluated over a 3-month period. Eligible patients were adults (≥ 18 years of age) with a primary diagnosis of schizophrenia who were being treated with lurasidone (for the first time [i.e., they were lurasidone naive]) as part of routine clinical practice. Efficacy endpoints were changes in patient/caregiver treatment satisfaction (seven-point Likert scale from the Treatment Satisfaction Questionnaire for Medication), patient quality of life and functioning (QLS), investigator-rated global assessment of functioning (CGI-S, IAQ) after 6 weeks and 3 months of lurasidone, and number of relapses and hospitalizations. Results: Sixty-one patients were enrolled and 59 completed the study. The median dosage of lurasidone at baseline was 37.00 mg/day. The median duration of titration was 86.0 days (Min 28; Max 115 days); the median number of dosage changes was 1.0. At the end of 3-month observation period, the median dose of lurasidone was 74.00 mg/day. QoL and Functioning Score showed a trend of improvement over time, reaching a mean change from baseline of 9.8 at the end of the study. According to the CGI-S, the percentage of patients who were "markedly or severely ill" showed a continuous decrease from baseline to 3 months, from 62.29% to 8.20%. Patient satisfaction increased over time, with 80.32% of patients reporting that they were somewhat, fairly, or very satisfied (including 63.93% who were completely or very satisfied) at the end of the study. No relapses/hospitalizations for psychiatric reasons were reported. Lurasidone was well tolerated with no safety concerns or discontinuations due to AEs. Conclusions: Lurasidone represents a valid option for the treatment of schizophrenia and positively affects subjective well-being, quality of life and satisfaction. Trial registration: NCT06527885 retrospectively registered (01/08/2024). [ABSTRACT FROM AUTHOR]

A Brønsted acid-mediated insertion of thioureas/thioamides into sulfoxonium ylides to synthesise 40 thiazoles (34–95% yields) under mild, metal-free conditions is described. This process is scalable, substrate-tolerant (including both α-substituted and heterocyclic ylides/groups) and was successfully applied to the late-stage functionalisation of the complex chemical probe molecule (+)-JQ1. [ABSTRACT FROM AUTHOR]

The current study presents six D-π-A configured non-fullerene acceptor chromophores (BTI1-BTI6) derived from benzotriindole compound end-capped with hexyldicyanovinyl groups, referred to as BTI (2 T-DCV-Hex)3, through structural tailoring of different terminal acceptors. Optoelectronic characteristics of newly designed chromophores were determined via DFT study at B3LYP/6-31G (d,p) functional. Various analyses such as frontier molecular orbitals, density of states (DOS), transition density matrix (TDM), binding energy (Eb), and open circuit voltage (Voc) were conducted. All the derivatives exhibited a comparable band gap (2.45–2.70 eV) manifesting absorption bands in the UV-Visible spectrum (590–463 nm), in solvent as well as in gaseous phase. Interestingly, smaller Eb values of 0.170 and -0.099 eV were observed for BTI5 and BTI6, respectively, suggesting a greater degree of charge transfer and improved exciton dissociation in these derivatives. These findings are further supported by TDM and DOS analyses, which confirm that all the studied compounds exhibit a higher charge transfer rate from highest occupied orbital to lowest unoccupied orbital (HOMO to LUMO). In conclusion, the good photovoltaic response observed for all the compounds suggests that these chromophores are reasonable candidates for development of efficient organic solar cells. [ABSTRACT FROM AUTHOR]

A selective direct arylation of the different Csp2‐H bonds of imidazo[2,1‐b]thiazole with (hetero) aryl halides can be achieved simply by switching from a palladium catalyst system to the use of stoichiometric amounts of copper. The observed selectivity, also rationalized by DFT calculations, can be explained by a change in the mechanistic pathways between electrophilic palladation and base‐promoted C−H metalation. [ABSTRACT FROM AUTHOR]

Imaging biomarkers have changed the way we study Alzheimer's disease and related dementias, develop new therapeutics to treat the disease, and stratify patient populations in clinical trials. With respect to protein aggregates comprised of amyloid-b plaques and tau neurofibrillary tangles, Positron Emission Tomography (PET) has become the gold standard imaging modality for quantitative visualization. Due to high infrastructural costs, the availability of PET remains limited to large urban areas within high income nations. This limits access to leading edge medical imaging, and potentially access to new treatments, by millions of rural and remote residents in those regions as well as billions of people in middle- and low-income countries. Single Photon Emission Computed Tomography (SPECT) is a more widely available imaging alternative with lower infrastructural costs and decades of familiarity amongst nuclear medicine professionals. Recent technological advances have closed the gap in spatial resolution and quantitation between SPECT and PET. If effective SPECT radiotracers were available to visualize amyloid-b plaques, geographic barriers to imaging could be circumvented. In this review, we will discuss past efforts to develop SPECT radiotracers targeting amyloid-b plaques which incorporate the most used radionuclide in nuclear medicine: technetium-99m (99mTc; t1/2 = 6.01 h; g = 140 keV). While reviewing the various chemical scaffolds and chelates employed, the focus will be upon the impact to the pharmacological properties of putative 99mTc-based amyloid-targeting radiotracers. [ABSTRACT FROM AUTHOR]

We have developed one thermal and one light-mediated method for direct Minisci-type C–H amidation of 1,3-azoles, which are applicable to thiazoles, benzothiazoles, benzimidazoles, and for the first time, imidazoles. The new visible light-mediated approach can be rendered photosensitiser/photocatalyst-free and likely proceeds via an electron donor–acceptor (EDA) complex, the first direct Minisci-type amidation to do so. [ABSTRACT FROM AUTHOR]

Novel benzophenone–thiazole hybrids with different substituents were synthesized and evaluated for anti‐inflammatory activity using an ex vivo human whole‐blood assay. All hybrids (3c and 5a–h) showed significant anti‐inflammatory activity via prostaglandin E2 (PGE2) release inhibition. Moreover, 5c (82.8% of PGE2 inhibition), 5e (83.1% of PGE2 inhibition), and 5h (82.1% of PGE2 inhibition) were comparable to the reference drugs. Molecular docking revealed potential preferable binding to the active sites of cyclooxygenase 2 (COX‐2) and microsomal prostaglandin E synthase‐1 (mPGES‐1) enzymes. This study provides the first evidence that benzophenone–thiazole hybrids may also dock in mPGES‐1, a new attractive anti‐inflammatory drug target, besides providing promising ex vivo anti‐inflammatory activity. Thus, the novel hybrids are promising anti‐inflammatory lead compounds and highlight the significance of optimal substituent selection in the design of potent PGE2 inhibitors. [ABSTRACT FROM AUTHOR]

Preliminary ab initio calculations led to the synthesis of novel substituted thiazolium salts, analogs of Alagebrium, which were further explored in vitro for their potential as inhibitors of the glycation reaction utilizing three distinct assays: inhibition of fluorescent AGEs formation, anticrosslinking, and deglycation. Despite the unidirectionality of the assays, distinct differences were observed in the mechanisms of interference and activity manifestation by the compounds. The gathered data permitted the formation of hypotheses about the molecular fragments of the studied antiglycators that are of utmost significance in each assay, thereby guiding future design endeavors. Potential mechanisms of actions are discussed therein. The compound 4‐meth‐yl‐3‐[2‐(4‐methylbiphenyl‐4‐yl)‐2‐oxoethyl] thiazolium bromide displayed high activity across all three assays, establishing it as a lead compound. The cytotoxicological properties of the compounds were evaluated using LDH and MTT assays. However, the lead compound exhibited cytotoxicity, indicating the need for additional investigations aimed at decreasing toxicity while maintaining activity. The targeted thiazolium salts were synthesized through an N‐alkylation reaction between the corresponding thiazoles and phenacyl bromides. [ABSTRACT FROM AUTHOR]

Objective: synthesize thioacetamide-thiazole as key pharmacophore possessing acetylcholinesterase (AChE) inhibitory activity. Methods: Thirteen compounds (IIIa–IIIm) were synthesized by preparing differently substituted aminothiazoles and subsequently evaluated for AChE inhibitory and antioxidant activity. Results and Discussion: Compound (IIIk) (IC50 = 1.99 µM) exhibits promising AChE inhibitory activity amongvarious derivatives of the series. The antioxidant potential of synthesized compounds were determined by DPPH assay (IC50 = 1.10 to 15.45 µM). Compound (IIIk) exhibited the utmost antioxidant activity with IC50 = 1.10 µM. Further molecular docking, drug-likeness, and ADMET predictions of all synthesized compounds were also assessed with computational methods. The results unequivocally supported the in vitro studies of all derivatives by displaying good docking score with binding pocket of PDB4EY7. Conclusions: The study concluded that compound (IIIk) emerged as potential lead compound as AChE inhibitor for the development of new compounds as anti-Alzheimer's candidates. [ABSTRACT FROM AUTHOR]

Objective: Initiating urate‐lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of flare risk during the initiation and escalation of allopurinol and febuxostat, administered as a treat‐to‐target strategy with optimal anti‐inflammatory prophylaxis. Methods: This was a post‐hoc analysis of a 72‐week randomized, double‐blind, placebo‐controlled, noninferiority trial comparing the efficacy of allopurinol and febuxostat. For this analysis, the occurrence of flares was examined during weeks 0 to 24 when ULT was initiated and titrated to a serum urate (sUA) goal of less than 6 mg/dl (<5 mg/dl if tophi). Flares were assessed at regular intervals through structured participant interviews. Predictors of flare, including treatment assignment, were examined using multivariable Cox proportional hazards regression. Results: Study participants (n = 940) were predominantly male (98.4%) and had a mean age of 62.1 years with approximately equal proportions receiving allopurinol or febuxostat. Mean baseline sUA was 8.5 mg/dl and all participants received anti‐inflammatory prophylaxis (90% colchicine). In a multivariable model, there were no significant associations of ULT treatment (hazard ratio [HR] 1.17; febuxostat vs allopurinol), ULT‐dose escalation (HR 1.18 vs no escalation), prophylaxis type, or individual comorbidity with flare and no evidence of ULT‐dose escalation interaction. Factors independently associated with flare risk during ULT initiation/escalation included younger age, higher baseline sUA, and absence of tophi. Conclusion: These results demonstrate that gout flare risk during the initiation and titration of allopurinol is similar to febuxostat when these agents are administered according to a treat‐to‐target strategy using gradual ULT‐dose titration and best practice gout flare prophylaxis. [ABSTRACT FROM AUTHOR]

An ultrasound-assisted expedient protocol has been developed for the synthesis of imidazo[1,2- a ]pyridines and imidazo[2,1- b ]thiazoles by the C–H functionalization of ketones using a KI/ tert -butyl hydroperoxide catalytic system. The reaction takes place in water, a green solvent, and does not require a metal catalyst; it also gives good yields of the products. The method offers numerous noteworthy characteristics, including mild reaction conditions, the absence of a base, broad functional-group compatibility, and excellent reaction yields. Moreover, it avoids the use of costly and air-sensitive chemicals, and can be conducted under ambient reaction conditions. [ABSTRACT FROM AUTHOR]

The novel immobilization of L-Valine on superparamagnetic Fe3O4 nanoparticles was prepared using a simple protocol for the first time. This compound acts as a highly efficient and recyclable heterogeneous nanocatalyst for the synthesis of thiazole derivatives via a one-pot and multi-component condensation reaction of arylglyoxals monohydrate, cyclic 1,3-dicarbonyls, and thiobenzamides in a water solvent. The structure of the nanocatalyst was characterized and confirmed using various techniques, such as Fourier transform infrared spectroscopy (FT-IR), Energy Dispersive X-ray (XRD), scanning electron microscopy (SEM), thermogravimetric analysis (TG/DTA), and vibrating sample magnetometry (VSM). This heterogeneous nanocatalyst can be easily recovered from the reaction mixture by an external magnetic field and reused for subsequent reactions at least five times without losing significant catalytic activity. [ABSTRACT FROM AUTHOR]

Heterocyclic systems containing 2-(2-hydrazinyl) thiazole moieties were synthesized by heterocyclization of thiosemicarbazones with arylglyoxals and Meldrum's acid in ethanol and water 1:1 (v/v) under reflux conditions. The paper reports an efficient, facile, and environmentally friendly protocol via a novel one-pot three-component reaction to access a broad range of 2-(2-Hydrazinyl) thiazole derivatives. Products were isolated by plate chromatography and their structures were established from their spectroscopic data, then the antibacterial and antioxidant activity of synthesized 2-(2-hydrazinyl) thiazole derivatives were evaluated, and demonstrated encouraging antibacterial activity against Staphylococcus aureus as a gram positive bacteria and Escherichia coli as a gram negative bacteria. Furthermore, when representative products were assessed for radical scavenging activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH0), high antioxidant effects were observed, indicating their potential safety for use in pharmacological studies. [ABSTRACT FROM AUTHOR]

Abstract It was known that the majority of viral infections start off as cutaneous eruptions, which heal on their own in most cases. The prognosis is dependent on the state of immunologic surveillance, just like in other infectious disorders. Therefore, those who are immunosuppressed are more in danger. But recently it’s becoming increasingly clear that eruptions that were once thought to be benign diseases can really cause problems and even death, even in immunocompetent patients. Hence, in this article, our goal was to identify possible potential antiviral candidates. We have synthesized a series of bis-thiazole derivatives via the reaction of bis-thiosemicarbazone derivative 3 with hydrazonoyl chlorides and haloketones in an effort to examine their potential antiviral properties and interactions with the main protease of Coxsackievirus B. Spectroscopic methods and elemental analysis were used to corroborate the structures of the novel bis-thiazole derivatives. The most potent derivative, bis-thiazole derivative 7a, was found to have the strongest antiviral activity against Coxsackievirus B (Cox B). Further investigation into its mode of action indicated that compound 7a has a dual activity that inhibits viral adsorption and replication. The efficacy of many compounds against Coxsackievirus adenovirus targets was assessed using molecular docking. The findings revealed that compounds 7a, 7c, 11b and 11c have high binding energies, efficiently engaging the active sites of essential Cox B virus proteins such as the Coxsackievirus adenovirus receptor (CAR), 3C-protease, and RNA-dependent RNA polymerase (RdRp). These interactions involved a variety of chemical bonding types, indicating that these substances can inhibit enzyme activity while also exhibiting substantial antiviral effects involving viral replication and adsorption. Furthermore, the computational ADMET study of these compounds indicated conformance to Lipinski’s criteria, implying positive physicochemical properties. Furthermore, MD simulations demonstrated stable complexes of 7a and 11b with Coxsackievirus adenovirus receptor (CAR), 3C-protease, and RNA dependent RNA polymerase (RdRp) with RMSD (0.1–0.30, 0.20–0.30, and 0.20–0.35 nm), RMSF (0.1–0.5 nm), and SASA (80–105, 140–150, and 220–235). These outcomes further reinforce the potential of these compounds in current antiviral drug development endeavors. The collective findings underscore the potential of these compounds as candidates for antiviral therapies against Coxsackievirus adenovirus.

Fluorenyl-hydrazonothiazole derivatives 2–7 were synthesized by the Hantzsch reaction from 2-(9H-fluoren-9-ylidene)hydrazine-1-carbothioamide (1) and the corresponding α-halocarbonyl compounds in THF or 1,4-dioxane solvent. A base catalyst is not necessary for synthesising thiazoles, but it can shorten the reaction time. The antimicrobial properties of all synthesized compounds were screened for multidrug-resistant microorganism strains. The minimum inhibitory concentration of the tested compounds against Gram-positive bacteria and fungi was higher than 256 μg/mL, but several compounds had activity against Gram-positive strains. [ABSTRACT FROM AUTHOR]

A series of 2-[(2,6-diarylpiperidin-4-yl)hydrazono]-2,3-dihydrothiazoles (25–40) were synthesized by the reaction of respective thiosemicarbazones (9–24) with phenacyl bromide in the presence of sodium acetate-acetic acid buffer and refluxing in ethanol for 12–16 h. The newly synthesized target compounds were characterized by elemental analysis, mass, FT-IR, 1H and 13C NMR spectroscopic methods. A Structure activity relationship study was carried out for the title compounds against a panel of bacterial strains viz Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhi, Bacillus subtilis and Klebsiella pneumonia and the fungal strains Cryptococcus neoformans, Candida albicans, Rhizopus sp, Aspergillus niger and Aspergillus flavus, respectively, using ciprofloxacin and amphotericin-B as standard drugs. These studies proved that compounds 26 and 34 against Staphylococcus aureus, 35 against P. aeruginosa,38 against B. subtilis, and 27 against K. pneumonia showed maximum inhibitory potency at the lowest concentration (6.25 µg/mL), whereas 26, 34 and 35 against C. neoformans and 26 and 27 against Candida albicans showed beneficial antifungal activity at a minimum concentration (MIC) of 6.25 µg/mL. [ABSTRACT FROM AUTHOR]

Antipsychotic-induced weight gain (AIWG) is a significant but frequently neglected adverse effect of first- and second-generation antipsychotic therapy, which may lead to cardiovascular disturbances. The present network meta-analysis (NMA) was conducted to evaluate and compare the effects of available treatment options in antipsychotic-induced weight gain (AIWG). The data was extracted from 68 relevant clinical trials after a literature search on MEDLINE/PubMed, Embase, Scopus, Cochrane databases and clinical trial registries. Random-effects Bayesian NMA was done to pool the effects across the interventions for the change in body weight from baseline. A network graph was built, a consistency model was run, node split analysis was performed, treatments were ranked as per the SUCRA score and meta-regression was done for the duration of therapy, baseline body weight and treatment strategy as the predictor variables. Finally, the results were sorted based on the certainty of evidence. The drugs showing significant reduction in body weight in order of magnitude of effect size include sibutramine 10 mg (−8.0 kg; −16. to −0.21), metformin 750 mg + lifestyle modification (−7.5 kg; −12 to −2.8), topiramate 200 mg (−7 kg; −10 to −3.4), metformin 750 mg (−5.7 kg; −9.3 to −2.1), topiramate 100 mg (−5.7 kg; −8.8 to −2.5), topiramate 50 mg (−5.2 kg; −10 to −0.57), liraglutide 1.8 mg (−5.2 kg; −10., −0.080), sibutramine 15 mg (−4.5 kg; −8.9 to −0.59), nizatidine 300 mg (−3.0 kg; −5.9 to −0.23) and metformin 1000 mg (−2.3 kg; −4.6 to −0.0046). There was no effect of duration of follow-up, baseline body weight and, preventive versus therapeutic strategy on weight reduction in AIWG. Metformin 750 mg with lifestyle modification was the most effective treatment for AIWG, followed by topiramate 200 mg, metformin 750 mg, and topiramate 100 mg with moderate certainty of evidence. • This network meta-analysis compared pharmacological agents used for antipsychotic-induced weight gain (AIWG) in schizophrenia. • Metformin (750 mg) with lifestyle modification is the best available treatment for AIWG, followed by topiramate (200 mg) and metformin (750 mg). • Other interventions which had a significant weight reduction effect were topiramate (50 mg and 100 mg), nizatidine 300 mg and metformin 1000 mg. • Liraglutide 3 mg had the highest magnitude of weight reduction as compared to placebo when meta-regression with baseline mean weight was done. [ABSTRACT FROM AUTHOR]

Described herein is a tandem reaction involving a copper chloride‐catalyzed cross‐coupling and an allene‐mediated cyclization of substituted ethynylimidazo[2,1‐b]thiazoles with aromatic N‐tosylhydrazones, producing naphtho[1′,2′4,5]imidazo [2,1‐b]thiazoles in very good yields. This protocol offers the advantages of one‐pot conversion from stable and readily available substrates as well as good functional group compatibility to prepare polycyclic N‐fused heteroaromatic systems. Moreover, the new compounds exhibited promising antitubercular activity. [ABSTRACT FROM AUTHOR]

This study effectively synthesized thiazole-4-carbohydrazide (SZCA) and its ionic salt SZCA⋅HClO4 and energetic complex Cu(SZCA)2(ClO4)2 (ECC-1). The new compound SZCA, SZCA⋅HClO4 and ECC-1 were fully characterized through elemental analysis, infrared spectroscopy, 13C NMR spectroscopy and thermal stability analysis. The combustion heat of ECC-1 was measured by oxygen bomb calorimetry, and its detonation performance was predicted by Kamlet-Jacobs formula and EXPLO5, respectively. The mechanical sensitivity of ECC-1 was tested using BAM method. In particular, we comprehensively evaluated the initiation ability of ECC-1 through lead plate destruction experiment and laser initiation experiment. The results show that ECC-1 have a decomposition temperature of 236 °C, exhibits acceptable mechanical sensitivity (impact sensitivity: 3.4 J, friction sensitivity: 4 N), and decent detonation properties (D: 6.6 km s-1, P: 21.3 GPa). And ECC-1 could be initiated by a single-pulse laser (λ: 808 nm, P: 20 W, t: 3 ms), and successfully detonated the next charge, such as RDX and CL-20. [ABSTRACT FROM AUTHOR]

The escalating incidence of bacterial resistance to commonly prescribed antibiotics underscores the urgent need for the rapid development of innovative antibacterial medications. Heterocyclic compounds, particularly nitrogen‐containing heterocycles like pyrazoles and thiazoles, have garnered attention for their diverse biological activities, including antimicrobial properties. Here, we present a green and efficient multicomponent synthesis method for fourteen novel benzothiazole‐tethered pyrazole derivatives. Utilizing the deep eutectic solvent glycerol/K2CO3 as a base‐catalytic reaction medium at 70 °C, this synthesis approach yielded promising compounds exhibiting substantial antimicrobial activity against various pathogenic microorganisms such as Staphylococcus aureus, Bacillus cereus, and Candida albicans. Among these, 4‐(benzo[d]thiazol‐2‐yl)‐3‐(4‐nitrophenyl)‐1‐phenyl‐1H‐pyrazol‐5‐amine emerged as the most promising candidate, showcasing significant inhibitory potentials with CZD values of 24 mm, 21 mm, and 26 mm for S. aureus, B. cereus, and C. albicans, respectively. Molecular docking studies further supported the experimental observations, revealing the high binding affinity of the compound to the nitroreductase enzyme with a binding score of −8.5 kcal/mol. These findings underscore the potential of these synthesized compounds as antimicrobial agents and suggest avenues for future research in exploring their structure‐activity relationships and therapeutic applications in combating bacterial infections. [ABSTRACT FROM AUTHOR]

One of the most serious future challenges to health care professionals is the emergence of multi-drug resistance pathogenic microbes that rapidly develop resistance to currently used antibiotics. So, as a way to overcome the antimicrobial drug-resistance problems, it is urgent need to synthesize several new lead molecules that are expected to have antibacterial and antifungal activities. So, some new thiazolidinone and methylthiazole derivatives incorporating benzodioxole nucleolus were constructed. Two different series of N-substituted thiosemicarbazones carrying a benzodioxole nucleus were synthesized through mutation reaction of the different aromatic and heterocyclic aldehydes with benzodioxolyl thiosemicarbazide. Cycloalkylation reaction of the latter thiosemicarbazones through with both of the ethyl chloroacetate or chloroacetone gave the thiazolidin-4-ones or 4-methylthiazoles, respectively. The antimicrobial activity of the thiazolidin-4-one and 4-methylthiazole derivatives was investigated. All of compounds showed from weak to moderate effects toward all tested bacteria. [ABSTRACT FROM AUTHOR]

Visible-light photocatalytic reactions between enaminones and thioureas leading to thiazole products have been achieved. The annulation process consists of tandem C–S and C–N bond formation by running reactions under air atmosphere at ambient temperature. Broad substrate tolerance of the sustainable protocol has been verified by the practical synthesis of divergent thiazoles with both monocyclic and fused cyclic structures. [ABSTRACT FROM AUTHOR]

Comprehensive Summary: A novel and eco‐friendly electrochemical activation of trifluoromethyl thianthrenium triflate (TT–CF3+OTf−) for trifluoromethylation of imidazole‐fused heteroaromatic compounds was established. This method involves the direct electrolysis of TT–CF3+OTf− without the requirement of external oxidants or catalysts, aligning with the principles of green chemistry. A wide range of imidazole‐fused heteroaromatic compounds including imidazo[1,2‐a]pyridines and benzo[d]imidazo[2,1‐b]thiazoles have been successfully trifluoromethylated using this technique, exhibiting excellent compatibility with various functional groups and a broad substrate scope. Moreover, the method's applicability for one‐pot sequential reactions enables the reduction of waste and resource consumption by eliminating the need for intermediate purification steps. [ABSTRACT FROM AUTHOR]

Gout is characterized by monosodium urate (MSU) crystal deposition secondary to hyperuricemia. Gout is associated with metabolic syndrome (MetS) and its related comorbid conditions such as cardiovascular disease (CVD). Major advances have been made in the comprehension of the link between MetS and gout. Despite observational studies suggesting an association between MetS-related conditions and hyperuricemia, there is no proof of causality. Most studies using Mendelian randomization did not find hyperuricemia as a causal factor for MetS-related conditions. In contrast, these conditions were found associated with hyperuricemia, which suggests a reverse causality. Among patients with gout, this high CVD risk profile implies the need for systematic screening for MetS-related conditions. Most international guidelines recommend systematic screening for and care of CVD and related risk factors in patients with gout. Some anti-hypertensive agents, such as losartan and calcium channel blockers, are able to decrease serum urate (SU) levels. However, there are potential interactions between gout management therapies and the treatment of metabolic diseases. Some data suggest that anti-inflammatory drugs used for gout flare treatment, such as colchicine or canakinumab, might have benefits for CVD. Regarding the impact of urate-lowering therapies on CVD risk, recent studies found a similar CVD safety profile for allopurinol and febuxostat. Finally, sodium-glucose cotransporter-2 inhibitors are promising for gout because of their ability to decrease SU levels and risk of recurrent flares. In this review, we focus on the clinical challenge of managing MetS in patients with gout, particularly older patients with co-medications. [ABSTRACT FROM AUTHOR]

Silica-decorated maghemite (γ-Fe2O3) nanoparticles have been prepared successfully through a simple co-precipitation method followed by coating with silica shell using tetraethoxysilane. Silica coating significantly enhanced the chemical and thermal stability of the iron oxide. 1,10‐Phenanthroline‐5,6‐diol (phendiol) was loaded onto the surface of silica-coated maghemite nanoparticles (γ-Fe2O3/SiO2 NPs) and reacted with Cu(NO3)2 · 3H2O to furnish the desired magnetic nanocatalyst (γ-Fe2O3@SiO2@Phen@Cu(II)). The catalyst was characterized by various physicochemical techniques such as Fourier transform-infrared spectroscopy, scanning electron microscopy, X-ray diffraction (XRD), energy‐dispersive X‐ray, vibrating sample magnetometry, thermo-gravimetric analysis, inductivity coupled plasma (ICP), transmission electron microscopy, and Ultraviolet-Visible spectroscopy (UV–Vis). Magnetic γ-Fe2O3@SiO2@Phen@Cu(II) was utilized as a catalyst for the synthesis of new thiazoles in ethanol as a solvent with excellent yield (88–97%) and short reaction time (5–15 min). The catalyst was easily separated from the reaction mixture using an external magnet and recycled for up to four cycles with no substantial loss of catalytic activities. [ABSTRACT FROM AUTHOR]

The van Leusen reaction utilizes p‐toluenesulfonylmethyl isocyanide as a versatile synthon for constructing nitrogen‐containing heterocycles, such as oxazoles, imidazoles, thiazoles, and pyrroles. In this study, the van Leusen imidazole reaction, employed for synthesizing potential Hsp90 inhibitors, yielded unexpected side products containing novel condensed tricycles, specifically 3a,8b‐dihydro‐1H‐benzofuro[2,3‐d]imidazoles. The mechanism behind the formation of this unprecedented fragment was further analyzed through quantum mechanical calculations and experimental investigations of the reaction outcome under different reaction conditions and with various substituents. Additionally, the stabilities of the products were evaluated. [ABSTRACT FROM AUTHOR]

Lupeol is one of the most important metabolite in the class of terpenoids and possess excellent anticancer, anti-inflammatory, anti-diabetic activities etc. In the present study, the different thiazoles and oxazoles bearing lupeol derivatives were prepared to enhance their biological activity. Initially, the in vitro cytotoxic activity results showed that the synthesized lupeol derivatives (9a–9j and 10a–10e) showed significant activity against various cancer cells and the compounds 9h and 10b exhibited excellent activity against CAL27 cells. Further, these compounds 9h and 10b arrest the cell cycle at S phase and induce the late apoptosis in CAL27 cells by downregulating the BcL2 and vimentin expression and upregulating the Bax gene expression. Moreover, the lupeol derivatives showed dose-dependent anti-inflammatory activity by inhibiting the secretion of IL-6 cytokines in LPS-induced Raw 264.7 cells. Together, these results clearly indicated that the thiazoles and oxazoles bearing lupeol derivatives can used as chemotherapeutic drugs against cancer and inflammatory diseases. [ABSTRACT FROM AUTHOR]

Macrocyclic peptides containing a thiazole or thiazoline in the backbone are considered privileged structures in both natural compounds and drug discovery, owing to their enhanced bioactivity, stability, and permeability. Here, we present the biocompatible synthesis of macrocyclic peptides from N‐terminal cysteine and C‐terminal nitrile. While the N‐terminal cysteine is incorporated during solid‐phase peptide synthesis, the C‐terminal nitrile is introduced during cleavage with aminoacetonitrile, utilizing a cleavable benzotriazole linker. This method directly yields the fully functionalized linear peptide precursor. The biocompatible cyclization reaction occurs in buffer at physiological pH and room temperature. The resulting thiazoline heterocycle remains stable in buffer but hydrolyzes under acidic conditions. While such hydrolysis enables access to macrocyclic peptides with a complete amide backbone, mild oxidation of the thiazoline leads to the stable thiazole macrocyclic peptide. While conventional oxidation strategies involve metals, we developed a protocol simply relying on alkaline salt and air. Therefore, we offer a rapid and metal‐free pathway to macrocyclic thiazole peptides, featuring a biocompatible key cyclization step. [ABSTRACT FROM AUTHOR]

The medicinal chemistry of ferrocene has gained its momentum after the discovery of biological activities of ferrocifen and ferroquine. These ferrocenyl drugs have been designed by replacing the aromatic moiety of the organic drugs, tamoxifen and chloroquine respectively, with a ferrocenyl unit. The promising biological activities of these ferrocenyl drugs have paved a path to explore the medicinal applications of several ferrocenyl conjugates. In these conjugates, the ferrocenyl moiety has played a vital role in enhancing or imparting the anticancer activity to the molecule. The ferrocenyl conjugates induce the cytotoxicity by generating reactive oxygen species and thereby damaging the DNA. In medicinal chemistry, the five membered nitrogen heterocycles (azoles) play a significant role due to their rigid ring structure and hydrogen bonding ability with the biomolecules. Several potent drug candidates with azole groups have been in use as chemotherapeutics. Considering the importance of ferrocenyl moiety and azole groups, several ferrocenyl azole conjugates have been synthesized and screened for their biological activities. Hence, in the view of a wide scope in the development of potent drugs based on ferrocenyl azole conjugates, herein we present the details of synthesis and the anticancer activities of ferrocenyl compounds bearing azole groups such as imidazole, triazoles, thiazole and isoxazoles. [ABSTRACT FROM AUTHOR]

Based on the tremendous pharmacological activities of compounds containing thiazole and carboxamide moieties, the current study aims to prepare new series of thiazole, pyrazole, pyridine, and thiophene derivatives incorporating thiazole carboxamide moiety. Construction of the target compounds was achieved via different chemical transformations and using easily accessible starting materials. The structures of the synthesized compounds were confirmed by all possible spectral and elemental analyses. Results from the in-silico studies showed different Lipophilicity (log p) and Number of Lipinsk's violations due to the presence of NH2, C≡N, OH, and C=O groups which make more electrostatic hydrogen bond interactions in compounds 17 and 20 which increase their TPSA (Å2). These results were confirmed through docking simulation with PDBID: 5I9I which showed the least binding affinity with different proteins, and optimization of these heterocyclic compounds with computational calculations and identification of their physical descriptors which showed more stabilities and directed us for biological evaluation for further studies. [ABSTRACT FROM AUTHOR]

Copyright of Duzce University Journal of Science & Technology is the property of Duzce University Journal of Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Surface adsorption is a convenient and readily available method for immobilizing enzymes on metal-organic frameworks (MOFs). Metal-organic framework-5 (MOF-5), isoreticular metal-organic frameworks-3 (IRMOF-3), and multivariate analysis of MOF-5/IRMOF-3 (MMI) with a half-amino group (-NH2) were prepared in this study. Thermomyces lanuginosus lipase (TLL) was chosen as a commercially available enzyme for immobilization on the surfaces of these MOFs. Briefly, 1.5 mg of TLL was added to 10 mg of the MOFs, and after 24 h, 67, 74, and 88% of the TLL was immobilized on MOF-5, IRMOF-3, and MMI, respectively. Fourier transform infrared spectroscopy, X-ray diffraction, thermogravimetric analysis, scanning electron microscopy, energy-dispersive X-ray analysis, and Brunauer–Emmett–Teller analysis were used to characterize the resulting biocomposites. TLL@MOF-5, TLL@IRMOF-3, and TLL@MMI exhibited activities of 55, 75, and 110 U/mg, respectively. Investigation of the activity and stability of the prepared biocatalysts showed that TLL immobilized on MMI was 2.34-fold more active than free TLL. TLL@MMI exhibited high stability and activity even under harsh conditions. After 24 h of incubation in a mixture of 50% (v/v) MeOH, TLL@MMI retained 80% of its activity, whereas TLL@MOF-5 and free TLL lost 50 and 60% of their activities, respectively. TLL@MMI was used to synthesize 2-arylidenehydrazinyl-4-arylthiozole derivatives (91–98%) in a one-pot vessel by adding benzaldehydes, phenacyl bromides, and thiosemicarbazide to water. The efficiency of the 4a derivative with free TLL was 43%, whereas that with TLL@MMI was 98%.

Thiazole derivatives have attracted considerable attention in medicinal chemistry due to their promising biological activities. This review article provides a comprehensive overview on the pharmaceutical applications of the thiazole derivatives, exploring their structural activity relationship and medical applications. We discuss the anti-cancer, anti-inflammatory, anti- oxidant, BSA and DNA interaction properties of thiazole derivatives highlighting their role in drug development. This review will be a valuable resource in medicinal chemistry. This could lead to development of drugs containing thiazoles and improve bio-compatibility and efficiency of derivatives.

Herein, a rapid, clean, less expensive and environmentally friendly route to a novel series of coumarins bearing thiazoles or 1,3,4-thiadiazoles was developed via grinding method under solvent conditions. Thus, 6-bromo-3-(2-bromoacetyl)-2-chromen-2-one was treated with cyanothioacetamide to produce thiazole-2-acetonitrile derivative 2, which was then transformed to iminocoumarins by reacting with hydroxyaldehydes. Hydrolysis of iminocoumarins by conc. HCl furnished coumarins. Furthermore, treatment of compound 2 with phenylisothiocyanate produced thioanilide which interacts with hydrazonoyl chloride and/or α-halocarbonyl compounds afforded 1,3,4-thiadiazole and thiophene derivatives, consequently. All the newly prepared coumarins were screened against six pathogenic microorganisms. The results indicated that compounds 7 and 12 were the most effective against Bacillus pumilis, while compound 4b was highly active against Streptococcus faecalis. Also, compound 5b was highly active against Enterobacter cloacae. Compounds 2 and 7 were higher active compared with reference drug ketoconazole against fungi Saccharomyces cerevisiae.

Objective: The aim of this prospective, double-blind, randomized controlled trial was to compare the effect of oral premedication of meloxicam, ketorolac, dexamethasone, ibuprofen, or placebo on the success of inferior alveolar nerve blocks (IANB) of mandibular posterior teeth in patients experiencing symptomatic irreversible pulpitis. Method and materials: Two hundred and fifty emergency patients in moderate to severe pain diagnosed with symptomatic irreversible pulpitis of a mandibular first or second molar randomly received, in a double-blind manner, identical capsules containing either meloxicam 7.5 mg, ketorolac 10 mg, dexamethasone 0.5 mg, ibuprofen 600 mg, or placebo 60 minutes before the administration of an IANB. Profound lip numbness was assessed after 15 minutes. Access cavities were then prepared and success of IANB was defined as no or mild pain (Heft-Parker visual analog scale recordings) during access preparation and root canal instrumentation. The data were analyzed using chi-square and Kruskal-Wallis tests. Results: The overall success rates for the meloxicam 7.5 mg, ketorolac 10 mg, dexamethasone 0.5 mg, and ibuprofen 600 mg groups were 52%, 64%, 54%, and 58%, respectively, with no significant differences in success rates among the premedications groups (P > .05). However, the tested premedications revealed significant differences compared with the placebo group (32% success rate) (P < .05). Conclusion: Premedication with meloxicam, ketorolac, dexamethasone, and ibuprofen increased the efficacy of IANB in mandibular molars with symptomatic irreversible pulpitis. [ABSTRACT FROM AUTHOR]

A unique series of compounds was prepared from glutaric acid and various 2-amino thiazoles via a simple yet efficient synthetic method at ambient temperature. The N-(thiazol-2-yl)piperidine-2,6-dione derivatives were synthesized and characterized using multiple physicochemical techniques, X-ray crystallography, and SHG analysis. 2 out of the 5 newly synthesized compounds displayed strong nonlinear optical (NLO) properties. All five compounds were studied computationally, and UV spectroscopy was used to confirm the second harmonic generation (SHG) phenomenon. It was found that the compounds having a non-centrosymmetric space group have a larger band gap than the centrosymmetric space group and thus have more SHG properties. Compounds with large band gaps also have the distinctive S⋯O interaction, contributing significantly to conformational control of the crystal's geometry. [ABSTRACT FROM AUTHOR]

An intermolecular copper catalyzed heteroannelation reaction using Csp3‐Csp3 radical coupling approach has been accomplished to synthesize 2,5‐diphenyl‐3‐(pyrimidin‐2‐yl)‐3,4‐dihydro‐2H‐pyrrolo[2,3‐d]thiazole. C−C coupling between 4‐thiazolidinones and O‐acetyl oximes under Cu catalyst further cyclizes to get the target molecule thiazolidine‐fused nucleus. This unified method offers access to novel fused heterocycles with pyrimidines bearing 4‐thiazolidinone in moderate to higher yields. The optimization study includes various copper catalysts, oxidants, bases and solvents at different temperatures. [ABSTRACT FROM AUTHOR]

A series of 4-hydroxy-6-methyl-3-(1-(4-(aryl/methyl)thiazol-2-yl)-1H-pyrazol-3-yl)-2H-pyran-2-ones 3a–h have been synthesized from aryl/methyl halomethylketones and a key pyrazole intermediate 1 using a convenient one-pot synthesis method. All compounds were characterized by NMR and MS, and the structure of three of them (3a, 3b and 3f) was resolved by X-ray diffraction. These heteroatom-rich thiazole compounds were then evaluated as inhibitors of Mycobacterium tuberculosis InhA, a key enzyme involved in the type II fatty acid biosynthesis pathway of the mycobacterium. Although inhibitory activities were found to be rather weak, molecular docking studies were also been carried out to understand a possible mode of interaction with key residues in the enzyme's active site. [ABSTRACT FROM AUTHOR]

Full landscapes of atomic interactions, including strong chemical bonds, intramolecular noncovalent and intermolecular, were calculated for a series of six highly polymorphic compounds, all of which exhibit pronounced biological activity: sulfapyridine, sulfamerazine, sulfamethoxazole, sulfathiazole, chlorpropamide and tolbutamide. To ensure strict and unambiguous characterization of atomic bonding, the method of molecular Voronoi–Dirichlet polyhedra (MVDP) was employed. Conformational differences among molecules within polymorphic families were quantified in terms of the peculiarities of the intramolecular noncovalent interactions being realized. On the basis of the k–Φ criterion all the studied molecules were proved to show unique systems of intramolecular noncovalent interactions thus being unique conformers. The relative importance of intramolecular noncovalent interactions, which have the maximum effect on the conformation of the respective molecules, was assessed. Good correlation was observed between the characteristics of π stacking calculated using the MVDP method and experimental polymorphic transition temperatures of sulfamethoxazole. The ratio of crystal volume with respect to strong chemical bonds, intramolecular noncovalent and intermolecular interactions for a large amount of unrelated compounds was analyzed. [ABSTRACT FROM AUTHOR]

Objectives Frequent gout attacks in the initial introduction of urate-lowering therapy (ULT) are significant causes of poor drug adherence and ULT discontinuation. Initial low-dose urate-lowering drugs may be effective in reducing gout flares, however robust evidence is sparse. The aim of this study was therefore to assess the association of initial dose urate-lowering drugs with gout flares in adult males with gout during the initial introduction of ULT. Methods This cohort study obtained data on consecutive gout patients from a single-centre gout cohort study from August 2017 to October 2020. A standard questionnaire was applied to collect demographic and clinical information, and biochemical parameters were tested on the same day. The primary endpoint was to estimate the association of initial dose febuxostat with gout flares, using Cox hazard models with inverse probability of treatment weighting (IPTW). Results A total of 582 gout patients were included in this study. During the 6-week follow-up, 71 (12.2%) patients suffered gout flares. In the main analysis using Cox hazard models with IPTW, compared with colchicine prophylaxis, initial low-dose febuxostat alone had no statistical significance with the increased risk of gout flares [hazard ratio (HR) 1.26; 95% CI 0.58, 2.72], while initial high-dose febuxostat was associated with an increased risk of gout flares (HR 3.08; 95% CI 1.34, 7.07). Conclusions This observational study demonstrated that initial low-dose febuxostat was equally effective in preventing gout flares as colchicine prophylaxis, while initial high-dose febuxostat alone was associated with an increased risk of gout flares. [ABSTRACT FROM AUTHOR]

A series of iridium(III) triimine complexes incorporating 2,2′:6′,2″-terpyridine (terpy) and 2,6-bis(thiazol-2-yl)pyridine (dtpy) derivatives were successfully designed and synthesized to investigate the impact of the peripheral rings (pyridine, thiazole) and substituents (thiophene, bithiophene, EDOT) attached to the triimine skeleton on their photophysical properties. The Ir(III) complexes were fully characterized using IR, 1H, elemental analysis and single crystal X-ray analysis. Their thermal properties were evaluated using TGA measurements. Photoluminescence spectra of [IrCl3L1–6] were investigated in solution at 298 and 77 K. The experimental studies were accompanied by DFT/TDDFT calculations. The photophysical properties of the synthesized triimine ligands and Ir(III) complexes were studied in detail by electronic absorption and emission. In solution, they exhibited photoluminescence quantum yields ranging from 1.27% to 5.30% depending on the chemical structure. The experimental research included DFT/TDDFT calculations. The photophysical properties of the synthesized triimine ligands and Ir(III) complexes were conducted using electronic absorption and emission techniques. In solution, they displayed photoluminescence quantum yields ranging from 1.27% to 5.30% depending on the chemical structure. [ABSTRACT FROM AUTHOR]

Novel thiazole-based hybrids (8a–g) and (9a–g) were developed and synthesized to create lead compounds with remarkable antibacterial efficacy. Several analytical methods were used to characterize the synthesized compounds, including NMR, IR, and HR-MS. Molecular docking against the DNA Gyrase B (PDB ID: 6YD9) was studied to have an extensive understanding of the binding interactions of thiazole-based hybrids with the protein of Escherichia coli. The 9e and 9g derivatives demonstrated outstanding in vitro inhibitory efficacy with minimum-inhibitory concentration (MIC) of 6.25 µg/ml and 12.5 µg/ml, respectively, against E. coli. The compound 9c showed better efficacy against S. pyogene (MIC value − 12.5 µg/ml) than the standard drugs. In general, trifluoromethyl-substituted compounds (9a–g) tended to interact with the target protein more than the chloro-substituted compounds (8a–g). The reason is that the lipophilicity generated by the trifluoromethyl group on the thiazepine core helped the molecules to penetrate the bacterial cell wall, which is lipophilic in nature. The increased hydrophobicity of the thiazole substituent contributed to the greater efficacy of compound 9e. Additionally, molecular dynamics simulations were carried out to evaluate the dynamic behavior and stability of the most anticipated compound, 9e, in a complex with the target protein. All synthesized compounds appear non-toxic and non-carcinogenic in living systems, according to in silico ADMET investigations. To aid the development of bioactive molecule design, the structure–activity relationship analysis of the newly synthesized hybrids' remarkable in vitro efficacy against different bacterial strains, is also discussed. [ABSTRACT FROM AUTHOR]

In this study, the focus was on synthesizing metal chelates of Fe(III), Ni(II), and Pd(II) using thiazole‐guanidine derivatives. Various spectral and analytical methods were employed to elucidate the structural characteristics and determine the molecular formulae of these metal chelates, including infrared (IR(, 1H‐NMR and 13C‐NMR, ultraviolet–visible (UV–vis), CHN, XRD data, mass spectrometry, thermal conduction, and measures of magnetism, were used to clarify the structures of these compounds. The optimized molecular structures have been scrutinized by the DFT method. Correlation between all spectroscopic methods and DFT calculation revealed an octahedral‐coordinating environment surrounding the Fe3+ ion, [Fe (BTG)2(NO3)2].NO3.2H2O and Ni2+, [Ni (BTG)2(NO3)2].H2O cation and distorted square planner surrounding Pd2+, [Pd (BTG) (COOCH3)2].2H2O cation. The examination of the stability and stoichiometry of complexes in solution using conventional techniques has been incorporated into the investigation's scope. Under mild reaction conditions, the green technique was employed to carry out a condensation reaction for aromatic aldehyde, rhodanine, pipredine, and 5‐aminotetrazol to generate derivatives of 6‐piperidin‐dihydro‐thia‐hexaaza‐s‐indacene derivatives. In comparison to our new complexes, all reaction conditions were optimized for those variable Lewis acid catalysts. In general, tests conducted under high yield, speedy, and environmentally friendly solvent (H2O/EtOH) conditions, the BTGPd catalyst showed superiority over others. Additionally, the hetero‐catalyst recovery proved successful and could be employed with the same efficiency up to six times before the efficiency started to decrease. The effectiveness of this catalytic procedure was validated through a thorough examination using density functional theory (DFT). The DFT analysis showcased the distinctive characteristics of this complex and proposed logical mechanisms that elucidated the crucial physical parameters responsible for the superior catalytic performance of the Pd(II) complex. [ABSTRACT FROM AUTHOR]

A new composite was fabricated via the covalent grafting of magnetic lidocaine–Cu complex on silica support. The novelty of this composite is being magnetic and nontoxic. It was characterized by various techniques including FT-IR, X-ray diffraction (XRD), FE-SEM, EDX-map, and VSM. The applicability of this composite as a catalyst in the synthesis of quinazolin-4-ones, benzo[d]thiazoles, and benzo[d]imidazoles were investigated. The catalyst is advantageous owing to its drug base, environmental friendliness, high efficiency, cheapness, easy separation due to being magnetic, and the possibility of being reused four times. [ABSTRACT FROM AUTHOR]

Starting compound 1 was synthesized according to reference.1 Benzylidene thiazole pyrimidin-3(5H)-ones were synthesized reactions of 1 with bromoacetic acid and various aryl-aldehydes in the same vessel via one-step, unlike studies in the literature. Quantum chemical parameters and full geometry optimizations for all compounds were computed using DFT based on B3LYP. Cytotoxic action potential of synthesized compounds was evaluated using trypan blue dye exclusion and MTT assays in different cell lines including adenocarcinoma alveolar basal epithelial-like adherent A549 cells, the colon adenocarcinoma HT-29 cells, prostate adenocarcinoma DU-145 cells, and diploid ARPE-19 retinal pigment epithelial cells. Embryotoxicity and genotoxicity assessments were performed on pluripotent human embryonal carcinoma NT2 and human lymphocyte cells, respectively. Compound A1 exhibited good anticancer activity on A549 and DU-145 cell lines, and the compounds including A3, 4, 6, and 9 induced cytotoxicity on A549 cells. The compounds A1-10 also showed a good biosafety profile at relatively lower concentrations. [ABSTRACT FROM AUTHOR]